Executive Summary

Q2 showed operational progress towards cosibelimab approval: FDA alignment on resubmission strategy in June, BLA resubmitted shortly thereafter, and FDA acceptance with a PDUFA date of December 28, 2024, driving the next major catalyst window .
Operating discipline materially narrowed losses: net loss improved to $(6.67)M ($0.18/sh) from $(16.52)M ($1.05/sh) YoY, with R&D down to $4.48M from $13.95M YoY and G&A $2.23M vs $2.28M YoY .
Liquidity was tight at quarter-end ($4.95M cash), but July’s ~$12.0M gross capital raise bolstered the balance sheet post-quarter; cash was $11.24M at 3/31 and $4.95M at 6/30 before the financing .
No product revenues; reported $41k related-party revenue; S&P Global consensus estimates were unavailable for comparison. Third-party aggregator data suggested a beat on EPS and revenue versus non-S&P estimates, but we anchor on S&P (unavailable) .

What Went Well and What Went Wrong

What Went Well

Regulatory path clarified: FDA alignment on the BLA resubmission strategy in June; BLA was resubmitted and accepted with a PDUFA date of Dec 28, 2024 (“working with the FDA…to potentially deliver this important therapeutic option…”) .
Cost control: R&D expenses fell to $4.48M from $13.95M YoY and G&A to $2.23M from $2.28M YoY, narrowing net loss to $(6.67)M from $(16.52)M YoY .
Post-quarter liquidity action: ~$12.0M gross raised in July via a registered direct and concurrent private placement, extending runway into the PDUFA window .

What Went Wrong

Cash at quarter-end was low at $4.95M before the July raise, highlighting ongoing financing dependence .
Capital structure stress: negative stockholders’ equity of $(15.75)M and current liabilities of $21.42M vs total assets of $5.67M underscore balance sheet constraints ahead of commercialization .
No commercial revenue base; Q2 revenue was de minimis related-party revenue of $41k, emphasizing binary regulatory and partnering milestones for valuation support .

Financial Results

Metric	Q2 2023	Q1 2024	Q2 2024
Revenue ($USD Thousands)	31	0	41
R&D Expenses ($USD Thousands)	13,945	8,497	4,480
G&A Expenses ($USD Thousands)	2,281	2,451	2,234
Total Operating Expenses ($USD Thousands)	16,226	10,948	6,714
Net Loss ($USD Thousands)	(16,521)	(10,945)	(6,670)
Diluted EPS ($)	(1.05)	(0.33)	(0.18)
Cash & Equivalents, period-end ($USD Thousands)	N/A	11,241	4,951
Weighted Avg Shares (Basic & Diluted)	15,700,324	33,930,977	36,526,268

Additional context:

Post-quarter capital raise: ~$12.0M gross proceeds in July 2024 .
Balance sheet (6/30/24): total assets $5.67M; current liabilities $21.42M; stockholders’ equity $(15.75)M .

No segment reporting or meaningful gross/operating margin KPIs given the immaterial revenue base .

Guidance Changes

Metric	Period	Previous Guidance	Current Guidance	Change
Cosibelimab BLA status	2024 regulatory	Targeted mid-year BLA resubmission; working to resolve CMO inspection deficiencies and seek FDA alignment	FDA accepted resubmitted BLA; PDUFA goal date set for Dec 28, 2024	Milestone advanced (accepted; PDUFA set)
FDA alignment on BLA	Mid-2024	Plan to meet FDA to reach alignment on resubmission	Alignment reached with FDA in June; BLA resubmitted shortly thereafter	Achieved
Financing	Near-term	N/A (Q1 noted January raise of ~$14M gross)	~$12M gross raised in July via registered direct and private placement	Liquidity enhanced

The company does not provide quantitative financial guidance (revenue, margins, OpEx) .

Earnings Call Themes & Trends

(No Q2 2024 earnings call transcript was found; company appears not to have hosted a call. We searched filings and transcripts and found none for Q2 2024.) [ListDocuments: earnings-call-transcript=0]

Topic	Previous Mentions (Q-2 and Q-1)	Current Period (Q2 2024)	Trend
Regulatory/BLA for cosibelimab (cSCC)	Targeted mid-year BLA resubmission; working to resolve CMO issues; high confidence in data	Alignment reached; BLA resubmitted; FDA accepted resubmission; PDUFA Dec 28, 2024	Positive progression toward decision
Manufacturing/CMO remediation	CRL cited CMO inspection findings; working closely with CMO to address deficiencies	Belief that resubmission addresses CRL; continuing to work with FDA/CMO through review	Risk reduced but remains under review
Financing/liquidity	Multiple capital raises in 2023/Jan 2024; cash $4.9M at 12/31/23; $11.2M at 3/31/24	Cash $4.95M at 6/30/24; ~$12M gross raised in July 2024	Managed via opportunistic raises
Business development	N/A in prior two periods	Collaboration to explore cosibelimab with GC Cell’s Immuncell-LC (announced in July)	Early-stage BD optionality
Commercial readiness	Working on select long lead time launch prep activities (FY23 update)	Not updated beyond regulatory path in Q2 release	Neutral/pending approval

Management Commentary

“We’ve made significant recent progress… We are pleased to have reached alignment with the FDA… Shortly thereafter, we resubmitted our BLA, which was accepted… PDUFA goal date of December 28, 2024.” — James F. Oliviero, President & CEO .
Q1 color on resubmission planning: “Our CMO submitted to FDA their response to the inspection deficiencies… which we believe could allow for the resubmission of our BLA. We plan to meet with the FDA shortly… to reach alignment for a potential mid-year BLA resubmission.” .

Q&A Highlights

No Q2 2024 earnings call transcript located; no Q&A themes available for this quarter [ListDocuments: earnings-call-transcript=0].

Estimates Context

S&P Global (Capital IQ) Wall Street consensus for Q2 2024 EPS and revenue was unavailable via our data connection at this time. As a result, we cannot provide a definitive S&P-based beat/miss view.
For reference only (non-S&P): a third-party aggregator reported EPS of -$0.18 vs a -$0.30 estimate and revenue of $41k vs a $20k estimate, implying beats on both metrics; we do not anchor to this for our assessment .

Key Takeaways for Investors

The story is now binary around the Dec 28, 2024 PDUFA; regulatory alignment and acceptance de-risked the path but CMO/inspection execution remains an overhang through approval .
Operating expense reductions have meaningfully lowered cash burn, improving loss trajectory ahead of the decision window .
Liquidity is managed with opportunistic raises; $4.95M cash at 6/30/24 increased by ~$12M gross in July, but the balance sheet remains constrained with negative equity and sizable current liabilities .
No commercial revenue base; valuation and stock reactions likely hinge on regulatory outcome, potential partnering, and commercialization strategy if approved .
Optionality from BD (GC Cell combination exploration) could broaden the pipeline narrative post-approval but is early-stage .
Absent S&P consensus, traders should monitor company disclosures and FDA milestones rather than quarter-to-quarter estimate optics for this pre-revenue biotech .

Appendix: Additional Q2 Details and KPIs

Post-quarter financing: registered direct and concurrent private placement for ~$12.0M gross proceeds in July 2024 .
Balance sheet (6/30/24): total assets $5.67M; current liabilities $21.42M; stockholders’ equity $(15.75)M .
Income statement detail (Q2 2024): revenue $41k (related-party); R&D $4.48M; G&A $2.23M; loss from operations $(6.67)M; net loss $(6.67)M; EPS $(0.18) .

Relevant primary-source documents read in full:

Q2 2024 8-K (Item 2.02) and press release (Exhibit 99.1) with full financials and updates .
Q1 2024 8-K and press release for prior-quarter trend .
FY 2023 8-K press release for additional historical context .
Additional Q2-relevant press release: FDA alignment on BLA resubmission strategy (June 24, 2024) .

Checkpoint Therapeutics, Inc. (CKPT)·Q2 2024 Earnings Summary